Feasibility
ADVERSE EVENTS
Results showed good overall feasibility: 39 out of 52 assessed participants (75%) were considered candidates and invited to the study. All 39 invited participants chose to participate. However, 17 of 20 participants (85%) completed the treatment. Meanwhile, 34 of 39 (87%) completed all assessments at T1, T2, and T3. Dropout rates were slightly higher in the NeuroACT group (20%) compared with the TAU group (5%) post randomization, and no adverse events were reported. Two participants were included who had a lower score (20 and 23, respectively) on the PSS than the inclusion cut-off (PSS > 24) but instead met the inclusion criteria on QOLI. Five participants were included who had a higher score (1.9–2.9) in the QOLI than the inclusion cut-off (QOLI < 1.84) but instead met inclusion criteria on PSS.Treatment credibility (max score = 10) was rated as high (